Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Evolent Health, Inc.NYSE: EVH
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $26.63M (cash outflow) fell 58.8% year over year, behind the +384.3% change in trailing-twelve-month net income. Sequentially, it fell 93.8% from the prior quarter. Over 3 fiscal years it compounded at +211.5% a year.
Context
- Net income amounted to 30.9% of revenue in FY2025, up 28.5 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of $26.3M (+104.5%) for the fiscal year ending Dec 2026, a slowdown from the +840.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.63M-93.8% QoQ
- Last fiscal yearDec 2025
- -$579.4M+840.2% YoY
- LTMMar 2026
- -$527.72M+384.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -58.8% | -97.7% | -38.9 pp |
| 1 year | +840.2% | +104.5% | -735.7 pp |
| 3-year CAGR | +211.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (579.4M) USD
- Year-over-year change
- -840.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (579.4M) | -840.2% |
| FY2024 | 2024-12-31 | (61.62M) | +45.5% |
| FY2023 | 2023-12-31 | (113.04M) | -489.9% |
| FY2022 | 2022-12-31 | (19.16M) | +49.0% |
| FY2021 | 2021-12-31 | (37.6M) | — |
Net Income vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 net income of $527.72M is the largest of the 11 companies compared; the peer median is $120.4M.
- Its year-over-year change of +384.3% is the highest of 11, against a peer median of +25.5%.
- Net income amounts to 27.9% of revenue for EVH, versus a peer median of 60.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $527.72M | +384.3% | +211.5% | 27.9% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Mar 2026 | $328.6M | +96.4% | -4.1% | 412.0% | |
| LTM Dec 2025 | $314.85M | +37.9% | +28.0% | — | |
| LTM Mar 2026 | $294.57M | +62.0% | +27.1% | 411.2% | |
| LTM Mar 2026 | $187.54M | +33.9% | — | 21.3% | |
| LTM Mar 2026 | $145.24M | +14.0% | +65.2% | — | |
| LTM Mar 2026 | $95.55M | +13.7% | -10.5% | 148.1% | |
| LTM Mar 2026 | $75.77M | +17.1% | -23.0% | 73.6% | |
| LTM Mar 2026 | $32.44M | -80.4% | — | 0.9% | |
| LTM Mar 2026 | $19.92M | +4.2% | +14.9% | 6.4% | |
| Peer median (excluding EVH) | $120.4M | +25.5% | +21.0% | 60.9% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (579.4M) |
| Depreciation & Amortization | 60.04M | 67.2M | 123.42M | 125.62M | 122.65M |
| Deferred Income Tax | (526K) | 342K | (31.27M) | (2.82M) | (2.98M) |
| Stock-Based Compensation | 16.71M | 33.98M | 40.5M | 39.75M | 39.74M |
| Change in Working Capital | (22.49M) | (104.44M) | 21.89M | (116.56M) | (57.38M) |
| Accounts Receivables | (24.76M) | (102.98M) | (164.69M) | 32.06M | 73.7M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.25M | 13.17M | (6.72M) | 4.25M | 6.64M |
| Other Working Capital | (4.98M) | (14.63M) | 193.31M | (152.87M) | (137.73M) |
| Other Non-Cash Items | 22.62M | 10.53M | 101.09M | 34.4M | 516.23M |
| Operating Cash Flow | 38.75M | (11.55M) | 142.58M | 18.77M | 38.84M |
| Capital Expenditures | (24.98M) | (38.36M) | (28.75M) | (24.89M) | (34.09M) |
| Acquisitions (Net) | 14.22M | 5.55M | 870K | (30.73M) | (57.44M) |
| Purchases of Investments | (3M) | (5.55M) | 0 | (7.32M) | (1M) |
| Sales of Investments | 500K | 5.55M | 0 | 7K | 986K |
| Other Investing Activities | (2.53M) | (226.31M) | (387.67M) | 0 | 91.31M |
| Investing Cash Flow | (15.79M) | (259.12M) | (415.54M) | (62.93M) | (233K) |
| Debt Repayment | (37.69M) | 219.74M | 183.29M | 58.58M | 65.06M |
| Common Stock Issued | 13.29M | 4.45M | 180.52M | 3.46M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (40M) |
| Dividends Paid | (1.3M) | (14.88M) | (18.79M) | (20.09M) | (11.13M) |
| Other Financing Activities | (3.85M) | (77.77M) | (63.68M) | (42.52M) | (49.86M) |
| Financing Cash Flow | (29.55M) | 131.54M | 281.34M | (565K) | (35.92M) |
| Effect of Forex Changes | (52K) | (657K) | (79K) | (229K) | 11.81M |
| Net Change in Cash | (6.64M) | (139.78M) | 8.3M | (44.96M) | 14.49M |
| Free Cash Flow | 13.76M | (49.91M) | 113.84M | (6.13M) | 4.76M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.